{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:48:17Z","timestamp":1793645297638,"version":"4.5.1"},"reference-count":116,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070758"],"award-info":[{"award-number":["82070758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2020SK2084"],"award-info":[{"award-number":["2020SK2084"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2019JJ40413"],"award-info":[{"award-number":["2019JJ40413"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>This study investigated the management and clinical outcomes along with associated factors of posterior reversible encephalopathy syndrome (PRES) in childhood hematologic\/oncologic diseases. We present data from children with hematologic\/oncologic diseases who developed PRES after treatment of the primary disease with chemotherapy and hematopoietic stem cell transplantation (HSCT) at 3 medical centers in Changsha, China from 2015 to 2020, and review all previously reported cases with the aim of determining whether this neurologic manifestation affects the disease prognosis. In the clinical cohort of 58 PRES patients, hypertension [pooled odds ratio (OR) = 4.941, 95% confidence interval (CI): 1.390, 17.570; <jats:italic>P<\/jats:italic> = 0.001] and blood transfusion (OR = 14.259, 95% CI: 3.273, 62.131; <jats:italic>P<\/jats:italic> = 0.001) were significantly associated with PRES. Elevated platelet (OR = 0.988, 95% CI: 0.982, 0.995; <jats:italic>P<\/jats:italic> &amp;lt; 0.001), hemoglobin (OR = 0.924, 95% CI: 0.890, 0.995; <jats:italic>P<\/jats:italic> &amp;lt; 0.001), and blood sodium (OR = 0.905, 95% CI: 0.860, 0.953; <jats:italic>P<\/jats:italic> &amp;lt; 0.001), potassium (OR = 0.599, 95% CI: 0.360, 0.995; <jats:italic>P<\/jats:italic> = 0.048), and magnesium (OR = 0.093, 95% CI: 0.016, 0.539; <jats:italic>P<\/jats:italic> = 0.008) were protective factors against PRES. Data for 440 pediatric PRES patients with hematologic\/oncologic diseases in 21 articles retrieved from PubMed, Web of Science, and Embase databases and the 20 PRES patients from our study were analyzed. The median age at presentation was 7.9 years. The most common primary diagnosis was leukemia (62.3%), followed by solid tumor (7.7%) and lymphoma (7.5%). Most patients (65.0%) received chemotherapy, including non-induction (55.2%) and induction (44.8%) regimens; and 86.5% used corticosteroids before the onset of PRES. Although 21.0% of patients died during follow-up, in most cases (93.2%) this was not attributable to PRES but to severe infection (27.3%), underlying disease (26.1%), graft-vs.-host disease (14.8%), multiple organ dysfunction syndrome (8.0%), and respiratory failure (3.4%). PRES was more common with HSCT compared to chemotherapy and had a nearly 2 times higher mortality rate in patients with oncologic\/hematologic diseases than in those with other types of disease. Monitoring neurologic signs and symptoms in the former group is therefore critical for ensuring good clinical outcomes following treatment of the primary malignancy.<\/jats:p>","DOI":"10.3389\/fped.2021.678890","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T13:38:08Z","timestamp":1625146688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic\/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size"],"prefix":"10.3389","volume":"9","author":[{"given":"Marady","family":"Hun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin S.","family":"Abdirahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senlin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phanna","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithea","family":"Phorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuqing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3322\/caac.21585","article-title":"Adolescent and young adult oncology-past, present, and future","volume":"69","author":"Close","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"B2","volume-title":"North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Analytic File 1995-2015 [Internet]","year":"2016"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrclinonc.2011.95","article-title":"Challenging issues in pediatric oncology","volume":"8","author":"Pui","year":"2011","journal-title":"Nat Rev Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.seminoncol.2008.07.008","article-title":"Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group","volume":"35","author":"O'Leary","year":"2008","journal-title":"Semin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3389\/fphar.2020.01184","article-title":"Pharmacogenomics as a tool to limit acute and long-term adverse effects of chemotherapeutics: an update in pediatric oncology","volume":"11","author":"Bernsen","year":"2020","journal-title":"Front Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1200\/jco.20.00493","article-title":"Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study","volume":"38","author":"Dixon","year":"2020","journal-title":"J Clin Oncol."},{"key":"B9","volume-title":"SEER Cancer Statistics Review, 1975-2014, (ed April 2017).","author":"Howlader","year":"2017"},{"key":"B10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fneur.2020.00938","article-title":"Analysis of risk factors associated with poor outcome in posterior reversible encephalopathy syndrome after treatment in children: systematic review and meta-analysis","volume":"11","author":"Hun","year":"2020","journal-title":"Front Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e27594","DOI":"10.1002\/pbc.27594","article-title":"Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: clinical characteristics, risk factors, course, and outcome of disease","volume":"66","author":"Anastasopoulou","year":"2019","journal-title":"Pediatr Blood Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ejh.12984","article-title":"A survey on hematology-oncology pediatric AIEOP centres: the challenge of posterior reversible encephalopathy syndrome","volume":"100","author":"Zama","year":"2018","journal-title":"Eur J Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1182\/blood-2018-99-115808","article-title":"Posterior reversible encephalopathy syndrome in pediatric oncology and post bone Marrow transplant: single center experience and systematic review","volume":"132","author":"Shash","year":"2018","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2017-04-742320","article-title":"How I treat pediatric venous thromboembolism","volume":"130","author":"Young","year":"2017","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.bbmt.2017.05.033","article-title":"Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies","volume":"23","author":"Gaziev","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/s41409-020-0894-5","article-title":"Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes","volume":"55","author":"Chen","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jnnp-2017-316225","article-title":"Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?","volume":"89","author":"Gao","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1177\/0883073816643409","article-title":"Imaging findings in pediatric posterior reversible encephalopathy syndrome (PRES): 5 years of experience from a Tertiary Care Center in India","volume":"31","author":"Gupta","year":"2016","journal-title":"J Child Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2019.07.007","article-title":"Epidemiology, comorbidities, and outcomes of posterior reversible encephalopathy syndrome in children in the United States","volume":"103","author":"Thavamani","year":"2019","journal-title":"Pediatr Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.pediatrneurol.2013.06.007","article-title":"Posterior reversible encephalopathy syndrome: incidence and associated factors in a pediatric critical care population","volume":"49","author":"Raj","year":"2013","journal-title":"Pediatr Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/10428194.2020.1832658","article-title":"Patterns, risk factors and outcome predictors of posterior reversible encephalopathy syndrome in pediatric cancer patients","volume":"62","author":"Hafez","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e13459","DOI":"10.1111\/ctr.13459","article-title":"Severe hypertension is an independent risk factor for posterior reversible encephalopathy syndrome post-hematopoietic cell transplantation in children with thalassemia major","volume":"33","author":"Li","year":"2019","journal-title":"Clin Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2019.08.007","article-title":"Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: a retrospective monocentric study","volume":"72","author":"Danhofer","year":"2019","journal-title":"Seizure."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/MPH.0000000000001009","article-title":"Posterior reversible encephalopathy syndrome: risk factors and impact on the outcome in children with acute lymphoblastic leukemia treated with nordic protocols","volume":"40","author":"Banerjee","year":"2018","journal-title":"J Pediatric Hematol Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/ane.12570","article-title":"Prognostic factors in children with PRES and hematologic diseases","volume":"134","author":"Tambasco","year":"2016","journal-title":"Acta Neurol Scand."},{"key":"B29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pediatrneurol.2016.09.001","article-title":"Posterior reversible encephalopathy syndrome: a comparative study of pediatric versus adult patients","volume":"65","author":"Habetz","year":"2016","journal-title":"Pediatr Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/j.bbmt.2020.08.021","article-title":"Posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation in pediatric patients with fanconi anemia, a prospective study","volume":"26","author":"Behfar","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e26531","DOI":"10.1002\/pbc.26531","article-title":"Calcineurin inhibitor-free strategies for prophylaxis and treatment of GVHD in children with posterior reversible encephalopathy syndrome after stem cell transplantation","volume":"64","author":"Shkalim-Zemer","year":"2017","journal-title":"Pediatr Blood Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/annonc\/mdq382","article-title":"Posterior reversible encephalopathy syndrome in childhood cancer","volume":"22","author":"de Laat","year":"2011","journal-title":"Ann Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol."},{"key":"B34","unstructured":"WellsGA\n            SheaB\n            O'ConnellDPJ\n            WelchV\n            LososM\n          Ottawa Health Research InstituteThe Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses2011"},{"key":"B35","first-page":"5","article-title":"Identifying and measuring heterogeneity","author":"Deeks","year":"2011","journal-title":"The Cochrane Handbook for Systematic Reviews of Interventions Version."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.23736\/s0026-4946.19.05675-5","article-title":"Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia during remission induction chemotherapy: a single-center retrospective study","author":"Lin","year":"2019","journal-title":"Minerva Pediatrica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MPH.0000000000001190","article-title":"PRES in pediatric HSCT: a single-center experience","volume":"40","author":"Kapoor","year":"2018","journal-title":"J Pediatr Hematol Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00381-017-3664-y","article-title":"PRES in the course of hemato-oncological treatment in children","volume":"34","author":"Musiol","year":"2018","journal-title":"Childs Nerv Syst."},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00381-017-3640-6","article-title":"Posterior reversible encephalopathy syndrome (PRES) due to neuroblastoma in a child presenting with acute hydrocephalus","volume":"34","author":"Aureli","year":"2018","journal-title":"Childs Nerv Syst."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.17.00089","article-title":"Posterior reversible encephalopathy syndrome in pediatric cancer clinical and radiologic findings","volume":"4","author":"Khan","year":"2017","journal-title":"J Global Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1097\/MPH.0000000000000728","article-title":"Posterior reversible encephalopathy syndrome and cerebral sinus thrombosis in a case of pediatric B-cell all","volume":"39","author":"Fraint","year":"2017","journal-title":"J Pediatr Hematol Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1097\/MPH.0000000000000827","article-title":"A case of all developing posterior reversible encephalopathy secondary to hyponatremia","volume":"39","author":"Eroglu","year":"2017","journal-title":"J Pediatr Hematol Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.21037\/qims.2016.10.07","article-title":"Posterior reversible encephalopathy syndrome after intrathecal methotrexate infusion: a case report and literature update","volume":"6","author":"Pavlidou","year":"2016","journal-title":"Quant Imaging Med Surg."},{"key":"B44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/pbc.25790","article-title":"Imaging patterns and outcome of posterior reversible encephalopathy syndrome during childhood cancer treatment","volume":"63","author":"Khan","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"B45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/MPH.0000000000000521","article-title":"Sorafenib-induced posterior reversible encephalopathy syndrome in a child with FLT3-ITD-positive acute myeloid leukemia","volume":"38","author":"Tavil","year":"2016","journal-title":"J Pediatr Hematol Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e27711","DOI":"10.1002\/pbc.27711","article-title":"Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: experience of a single center using BFM protocols","volume":"66","author":"Cifci Sunamak","year":"2019","journal-title":"Pediatric Blood Cancer."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e44534","DOI":"10.1371\/journal.pone.0044534","article-title":"Determinants of recovery from severe posterior reversible encephalopathy syndrome","volume":"7","author":"Legriel","year":"2012","journal-title":"PLoS ONE."},{"key":"B48","first-page":"2617","article-title":"Management of CNS toxicity of chemotherapy and targeted agents: 2020","volume":"10","author":"Juan Cintr\u00f3n-Garc\u00eda","year":"2020","journal-title":"Am J Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.pediatrneurol.2015.03.006","article-title":"Acute central nervous system complications in pediatric acute lymphoblastic leukemia","volume":"53","author":"Baytan","year":"2015","journal-title":"Pediatr Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneurol.2017.88","article-title":"Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics","volume":"13","author":"Argyriou","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity\u2013focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ctrv.2016.09.005","article-title":"Pediatric chemotherapy induced peripheral neuropathy: a systematic review of current knowledge","volume":"50","author":"Kandula","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin."},{"key":"B55","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.autrev.2015.05.006","article-title":"Posterior reversible encephalopathy syndrome\u2013Insight into pathogenesis, clinical variants and treatment approaches","volume":"14","author":"Granata","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e27999","DOI":"10.1002\/pbc.27999","article-title":"The spectrum of acute central nervous system symptoms during the treatment of childhood acute lymphoblastic leukaemia","volume":"67","author":"Banerjee","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B57","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0883073815589758","article-title":"Study of posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia after induction chemotherapy","volume":"31","author":"Tang","year":"2016","journal-title":"J Child Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1586\/14737140.2014.911089","article-title":"Central nervous system toxicities of chemotherapeutic agents","volume":"14","author":"Peddi","year":"2014","journal-title":"Expert Rev Anticancer Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.blre.2014.09.012","article-title":"The double-edged sword: neurotoxicity of chemotherapy","volume":"29","author":"Magge","year":"2015","journal-title":"Blood Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.bmt.1701575","article-title":"Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease","volume":"23","author":"Tse","year":"1999","journal-title":"Bone Marrow Transplantat."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1200\/JCO.2007.10.9991","article-title":"Dexamethasone-induced posterior reversible encephalopathy syndrome","volume":"25","author":"Irvin","year":"2007","journal-title":"J Clin Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord."},{"key":"B63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clml.2016.12.004","article-title":"Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) chemotherapy","volume":"17","author":"Floeter","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"key":"B64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jns.2017.06.044","article-title":"Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome","volume":"380","author":"Parikh","year":"2017","journal-title":"J Neurol Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3389\/fped.2020.00585","article-title":"Childhood posterior reversible encephalopathy syndrome: clinicoradiological characteristics, managements, and outcome","volume":"8","author":"Chen","year":"2020","journal-title":"Front Pediatr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ddg.13991","article-title":"Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy","volume":"18","author":"Stefanou","year":"2020","journal-title":"J Dtsch Dermatol Ges."},{"key":"B67","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1542\/peds.2014-2325","article-title":"PRES in children undergoing hematopoietic stem cell or solid organ transplantation","volume":"135","author":"Masetti","year":"2015","journal-title":"Pediatrics."},{"key":"B68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/107327481502200104","article-title":"Marques MD","volume":"22","author":"Radhika Dasararaju","year":"2015","journal-title":"Adverse Effects of Transfusion. Cancer Control."},{"key":"B69","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/CCM.0000000000002948","article-title":"Contemporary risk factors and outcomes of transfusion-associated circulatory overload","volume":"46","author":"Roubinian","year":"2018","journal-title":"Crit Care Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1212\/WNL.49.4.1174","article-title":"Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction","volume":"49","author":"Ito","year":"1997","journal-title":"Neurology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra1612789","article-title":"Indications for and adverse effects of red-cell transfusion","volume":"377","author":"Carson","year":"2017","journal-title":"N Engl J Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1001\/jama.2015.13977","article-title":"Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial","volume":"314","author":"Dhabangi","year":"2015","journal-title":"JAMA."},{"key":"B73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1126\/science.aax7171","article-title":"Cerebrospinal fluid influx drives acute ischemic tissue swelling","author":"Mestre","year":"2020","journal-title":"Science."},{"key":"B74","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1152\/japplphysiol.90349.2008","article-title":"Early brain swelling in acute hypoxia","volume":"107","author":"Dubowitz","year":"2009","journal-title":"J Appl Physiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12883-018-1194-1","article-title":"Posterior reversible encephalopathy syndrome with extensive cytotoxic edema after blood transfusion: a case report and literature review","volume":"18","author":"Nakamura","year":"2018","journal-title":"BMC Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/0271678X17736715","article-title":"Evaluating the involvement of cerebral microvascular endothelial Na(+)\/K(+)-ATPase and Na(+)-K(+)-2Cl(-) co-transporter in electrolyte fluxes in an in vitro blood-brain barrier model of dehydration","volume":"39","author":"Lykke","year":"2019","journal-title":"J Cereb Blood Flow Metab."},{"key":"B77","doi-asserted-by":"publisher","first-page":"365","DOI":"10.23750\/abm.v91i2.8685","article-title":"Posterior reversible encephalopathy syndrome in an oncological normotensive patient: evidence for a pathogenic role of concomitant low magnesium serum levels and chemotherapy treatment","volume":"91","author":"Zappia","year":"2020","journal-title":"Acta Biomed."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10072-018-3281-x","article-title":"Reversible cerebral vasoconstriction syndrome accompanied by hypomagnesemia","volume":"39","author":"Hokkoku","year":"2018","journal-title":"Neurol Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/pbc.24460","article-title":"Magnesium homeostasis and hypomagnesemia in children with malignancy","volume":"60","author":"Kaplinsky","year":"2013","journal-title":"Pediatr Blood Cancer."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1126\/science.aba8801","article-title":"Opening the floodgates to the brain","volume":"367","author":"Jonathan Moss","year":"2020","journal-title":"Science."},{"key":"B81","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3389\/fneur.2020.00591","article-title":"Cerebrospinal fluid hypovolemia and posterior reversible encephalopathy syndrome","volume":"11","author":"Zheng","year":"2020","journal-title":"Front Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1758834017736210","article-title":"Managing hyponatremia in lung cancer: latest evidence and clinical implications","volume":"9","author":"Fiordoliva","year":"2017","journal-title":"Ther Adv Med Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.critrevonc.2016.03.010","article-title":"Hyponatremia in cancer patients: time for a new approach","volume":"102","author":"Berardi","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0749-0704(18)30506-2","article-title":"Life-threatening fluid and electrolyte abnormalities associated with cancer","volume":"4","author":"Kopec","year":"1988","journal-title":"Crit Care Clin."},{"key":"B85","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3322\/caac.20124","article-title":"Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment","volume":"61","author":"Lewis","year":"2011","journal-title":"CA Cancer J Clin."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1097-0142(19930215)71:4<1309::AID-CNCR2820710423>3.0.CO;2-M","article-title":"Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center","volume":"71","author":"Vassilopoulou-Sellin","year":"1993","journal-title":"Cancer."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1210\/clinem\/dgaa547","article-title":"Risk of adverse clinical outcomes in hyponatremic adult patients hospitalized for acute medical conditions: a population-based Cohort study","volume":"105","author":"Kutz","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B88","doi-asserted-by":"publisher","first-page":"62","DOI":"10.7150\/jca.2.62","article-title":"Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia","volume":"2","author":"Shaikh","year":"2011","journal-title":"J Cancer."},{"key":"B89","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/ndt\/gfm571","article-title":"Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation","volume":"23","author":"Philibert","year":"2008","journal-title":"Nephrol Dialysis Transplant."},{"key":"B90","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jpm.2008.0200","article-title":"Predictive impact of electrolyte abnormalities on the admission outcome and survival of palliative care cancer referrals","volume":"12","author":"Alsirafy","year":"2009","journal-title":"J Palliative Med."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009311","article-title":"Posterior reversible encephalopathy syndrome with documented hyponatraemia","author":"Aulakh","year":"2013","journal-title":"BMJ Case Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.14581\/jer.14008","article-title":"Posterior reversible encephalopathy syndrome due to hyponatremia","volume":"4","author":"Jeon","year":"2014","journal-title":"J Epilepsy Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00467-006-0411-0","article-title":"Aquaporin-4 and brain edema","volume":"22","author":"Papadopoulos","year":"2007","journal-title":"Pediatric Nephrol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0750-7658(03)00009-1","article-title":"Osmotic cerebral oedema: the role of plasma osmolarity and blood brain barrier","volume":"22","author":"Boulard","year":"2003","journal-title":"Ann francaises d'anesthesie et de reanimation."},{"key":"B95","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ymgme.2019.10.011","article-title":"Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction","volume":"128","author":"Jaramillo-Calle","year":"2019","journal-title":"Mol Genet Metab."},{"key":"B96","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1055\/s-0037-1598251","article-title":"Should posterior reversible encephalopathy syndrome be mainly considered an epileptic disorder? Results of a sequential neurophysiological study in a pediatric Cohort","volume":"48","author":"Grioni","year":"2017","journal-title":"Neuropediatrics."},{"key":"B97","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.seminoncol.2006.03.006","article-title":"Neurologic complications of cancer chemotherapy","volume":"33","author":"Sul","year":"2006","journal-title":"Semin Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(03)13177-7","article-title":"Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia","volume":"361","author":"Savvidou","year":"2003","journal-title":"Lancet."},{"key":"B99","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.mehy.2014.02.022","article-title":"Posterior reversible encephalopathy syndrome: the endothelial hypotheses","volume":"82","author":"Marra","year":"2014","journal-title":"Med Hypotheses."},{"key":"B100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/0885066610393634","article-title":"Posterior reversible encephalopathy syndrome","volume":"27","author":"Staykov","year":"2012","journal-title":"J Intensive Care Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fneur.2020.00194","article-title":"Clinical and MRI features of posterior reversible encephalopathy syndrome with atypical regions: a descriptive study with a large sample size","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jns.2019.07.018","article-title":"Posterior reversible encephalopathy syndrome: a review with emphasis on neuroimaging characteristics","volume":"404","author":"Tetsuka","year":"2019","journal-title":"J Neurol Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1080\/10428194.2019.1594210","article-title":"Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management","volume":"60","author":"Ghali","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"B104","doi-asserted-by":"publisher","first-page":"421","DOI":"10.21037\/qims.2018.05.07","article-title":"Risk factors for poor outcome in posterior reversible encephalopathy syndrome: systematic review and meta-analysis","volume":"8","author":"Chen","year":"2018","journal-title":"Quant Imaging Med Surg."},{"key":"B105","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4065\/mcp.2009.0590","article-title":"Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings","volume":"85","author":"Fugate","year":"2010","journal-title":"Mayo Clin Proc."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1161\/STROKEAHA.109.575167","article-title":"Monitoring cerebral blood flow pressure autoregulation in pediatric patients during cardiac surgery","volume":"41","author":"Brady","year":"2010","journal-title":"Stroke."},{"key":"B107","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1055\/s-0040-1702934","article-title":"Etiologies, cerebral vasomotion, and endothelial dysfunction in the pathophysiology of posterior reversible encephalopathy syndrome in pediatric patients","volume":"18","author":"Ghali","year":"2020","journal-title":"J Pediatric Neurol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/bmt.2016.232","article-title":"Long-term outcome following cyclosporine-related neurotoxicity in paediatric allogeneic haematopoietic stem cell transplantation","volume":"52","author":"Straathof","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B109","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1111\/trf.12454","article-title":"How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention","volume":"53","author":"Andrzejewski","year":"2013","journal-title":"Transfusion."},{"key":"B110","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.pediatrneurol.2013.04.024","article-title":"Reversible posterior leukoencephalopathy syndrome after blood transfusion in a pediatric patient with sickle cell disease","volume":"49","author":"Kolovou","year":"2013","journal-title":"Pediatr Neurol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00134-006-0459-0","article-title":"Posterior reversible encephalopathy syndrome in intensive care medicine","volume":"33","author":"Servillo","year":"2007","journal-title":"Intensive Care Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00467-018-3946-y","article-title":"Management of high blood pressure in children: similarities and differences between US and European guidelines","volume":"34","author":"Brady","year":"2019","journal-title":"Pediatr Nephrol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1097\/HJH.0000000000001039","article-title":"2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents","volume":"34","author":"Lurbe","year":"2016","journal-title":"J Hypertens."},{"key":"B114","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pediatrneurol.2018.06.004","article-title":"Hospital emergency treatment of convulsive status epilepticus: comparison of pathways from ten pediatric research centers","volume":"86","author":"Vasquez","year":"2018","journal-title":"Pediatr Neurol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B116","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3322\/caac.21184","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.678890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T13:38:22Z","timestamp":1625146702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.678890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":116,"alternative-id":["10.3389\/fped.2021.678890"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.678890","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"article-number":"678890"}}